tak-715

TAK-715 is a potent and selective small molecule inhibitor of p38 mitogen-activated protein kinase alpha (p38α MAPK), developed by Takeda. It exhibits an IC50 of 7.1 nM for p38α and is approximately 28-fold more selective for p38α over p38β, with negligible inhibition of other kinases such as p38γ/δ, JNK1, ERK1, or IKKβ[1][3][5]. TAK-715 was investigated primarily as an anti-inflammatory agent for the treatment of chronic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. Its mechanism involves blocking the pro-inflammatory cytokine signaling pathway by inhibiting the production of tumor necrosis factor-alpha (TNF-α), interleukin (IL)-1, IL-6, cyclooxygenase-2-mediated prostanoids, nitric oxide production, and osteoclast differentiation[3][6]. The compound demonstrated good oral bioavailability in preclinical models and efficacy in animal models of arthritis but was discontinued after Phase II clinical trials due to insufficient efficacy or development criteria not being met[3].

Other names

TAK-715TAK715TAK 715